In December of 2019, China passed the Drug Administration Law that outlines the requirements for the establishment of a drug traceability system for medicines that updates the existing requirement. The National Medical Products Administration (NMPA) is tasked with implementing the program and, while the timeline continues to be finalized, the industry believes that compliance will be required across all medicines before the end of 2022. The industry also expects intermediate deadlines, the first of which is 31 Dec 2020 for specific drug classes. One decision that companies can—and should— be weighing immediately is how they will implement an effective, long-term product packaging, coding and serialization strategy for the China market.
Join Allan Bowyer, TraceLink’s Director of Industry Marketing and Community, for this informative overview to:
- Understand the new regulatory timeline: what is happening with the existing China serialization and traceability requirements, including considerations for the Dec 2020 deadline, and what the industry believes is coming.
- Get the new details on stakeholder roles and responsibilities including reporting, serialization, supply chain data exchange, and consumer engagement.
- Learn about the implications for new unique serialization and encoding standards for medicines— including how both China EDMC and GS1-compatible identifiers are allowed.
- Hear considerations specific to multinational companies selling into China, and their local affiliates.
Don’t miss this opportunity to get expert guidance on China’s directives so you can begin to include in your global serialization and compliance planning now.